Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Brilinta Ticagrelor Acute Coronary Syndromes Cancelled
Brilinta Ticagrelor Acute coronary syndromes Do not list Complete
Givlaari givosiran Acute hepatic porphyria (AHP) in adults Reimburse with clinical criteria and/or conditions Complete
Rylaze crisantaspase recombinant Acute lymphoblastic leukemia Reimburse with clinical criteria and/or conditions Complete
Blincyto Blinatumomab Acute Lymphoblastic Leukemia Reimburse with clinical criteria and/or conditions Complete
Rituxan Rituximab Acute Lymphoblastic Leukemia Do not reimburse Complete
Tecartus brexucabtagene autoleucel Acute lymphoblastic leukemia Reimburse with clinical criteria and/or conditions Complete
Clolar clofarabine Acute lymphoblastic leukemia CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Besponsa Inotuzumab Ozogamicin Acute Lymphoblastic Leukemia (ALL) Reimburse with clinical criteria and/or conditions Complete
Asparlas calaspargase pegol Acute lymphoblastic leukemia (ALL) Reimburse with clinical criteria and/or conditions Active